At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 199 enrolled
Drug / intervention
Everolimus (RAD001)drug
Likely dose
Everolimus (RAD001) 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm, Multicenter Phase II Study of Everolimus in Patients With Metastatic Colorectal Adenocarcinoma Whose Cancer Has Progressed Despite Prior Therapy With an Anti-EGFR Antibody (if Appropriate), Bevacizumab, Fluoropyrimidine, Oxaliplatin, and Irinotecan-based Regimens
In Brief
A Phase 2 clinical trial evaluating Everolimus (RAD001) for Colorectal Cancer. Completed, enrolled 199 participants across 1 site.
Detailed Summary
To assess the safety and efficacy of weekly (70 mg per week) and daily (10 mg per day) everolimus in patients with metastatic colorectal cancer whose cancer has progressed despite prior treatment with targeted therapy and chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedJan 2007
Primary CompletionMar 2009
TodayJul 2026
First PostedJan 8, 2007
Enrollment StartDec 1, 2006
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.5 years ago
Interventions
Everolimus (RAD001)drug
Everolimus was supplied in 5 mg tablets in blister packs.